Clinical Trials

Phase 2/3 Active not recruiting

HER2-positive Breast Cancer

NCT03315364 2026-04-01

OPTIMAL

549 enrolled

Breast Neoplasms, Recurrence

NCT06926868 2026-04-01

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

500 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07294508 2026-03-20

A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer

706 enrolled

Phase 2/3 Active not recruiting

Breast Neoplasms

NCT04191499 2026-03-17

INAVO120

325 enrolled 14 charts 3 FDA

Breast Neoplasms

NCT05860465 2026-01-14

Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer

254 enrolled

Phase 2/3 Not yet recruiting

Breast Neoplasms

NCT07294534 2025-12-19

A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat Cancer

817 enrolled

Breast Neoplasms

NCT06891833 2025-10-02

A Study of BL-M07D1 With or Without Pertuzumab Versus Taxane + Trastuzumab and Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer

120 enrolled

HER2-positive Breast Cancer

NCT05744687 2025-08-17

Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer

374 enrolled

Breast Neoplasms

NCT05555706 2025-04-15

Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer

62 enrolled

Phase 2/3 Active not recruiting

Triple Negative Breast Neoplasms

NCT05747794 2024-12-17

AIPAC-003

849 enrolled

Breast Neoplasms

NCT03500380 2024-02-20

A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases

Phase 2/3 Unknown

301 enrolled

Breast Diseases, Breast Neoplasms

NCT05802342 2023-04-06

A Multicenter, Randomized, Double-blind Phase II Trial to Evaluate GM1 Prevention of Peripheral Neuropathy in Patients With Breast Cancer

Phase 2/3 Unknown

150 enrolled

To Evaluate the Effectiveness of GM1 in the Prevention of Albumin-paclitaxel Therapy Induced Peripheral Neuropathy in Breast Cancer Patients

NCT04924699 2023-03-17

A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer

Phase 2/3 Unknown

350 enrolled

Breast Neoplasms

NCT03354611 2023-03-16

Contrast-Enhanced Cone Beam Breast CT for Diagnostic Breast Imaging

Phase 2/3 Terminated

21 enrolled

Breast Neoplasms

NCT04554056 2022-12-02

Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF

586 enrolled

Breast Cancer Female

NCT03674242 2022-08-01

Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone for the Treatment of TNBC (TRYbeCA-2)

Phase 2/3 Terminated

27 enrolled

Triple Negative Breast Neoplasms

NCT01881230 2019-02-21

tnAcity

191 enrolled 22 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00535418 2017-09-05

Optimal Duration of Pre-operative Treatment With Letrozole and to Correlate Clinical Efficacy With Appropriate Surrogate Markers

35 enrolled

Breast Neoplasms

NCT02651610 2017-07-11

Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer

Phase 2/3 Withdrawn

Breast Neoplasms

NCT01572727 2017-03-09

BELLE-4

416 enrolled 11 charts

Breast Neoplasms, Neoplasm Metastasis, Hereditary Sensory and Autonomic Neuropathies

NCT02213744 2017-01-06

HERMIONE

Phase 2/3 Terminated

113 enrolled

Breast Neoplasms

NCT01433562 2013-05-13

Efficacy and Safety of DLBS1425 as Neoadjuvant in Stage II or III Breast Cancer Patients

40 enrolled

Breast Neoplasms

NCT00243685 2012-01-26

Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis

BreastGynecologicSarcomaThoracic

150 enrolled

Breast Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Sarcoma

NCT00333047 2009-11-19

Letrozole in Metastatic Breast Cancer in Combination With Chemotherapy

24 enrolled

Breast Neoplasms

NCT00836654 2009-02-05

Study in EpCAM Positive Patients With Symptomatic Malignant Ascites Using Removab Versus an Untreated Control Group